Muscle-Invasive Bladder Cancer: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 153: | Line 153: | ||
=== Immunotherapy === | === Immunotherapy === | ||
==== | ==== Neoadjuvant ==== | ||
* PURE-01 (neoadjuvant pembrolizumab) | * PURE-01 (neoadjuvant pembrolizumab) | ||
** Phase II trial evaluated neoadjuvant pembrolizumab in 50 patients undergoing RC for MIBC and found that 42% of patients achieved pT0[https://www.ncbi.nlm.nih.gov/pubmed/30343614 §] | ** Phase II trial evaluated neoadjuvant pembrolizumab in 50 patients undergoing RC for MIBC and found that 42% of patients achieved pT0[https://www.ncbi.nlm.nih.gov/pubmed/30343614 §] | ||
==== | ==== <span style="color:#ff0000">Adjuvant</span> ==== | ||
* '''<span style="color:#ff00ff">CheckMate 274 (adjuvant nivolumab)</span>''' | * '''<span style="color:#ff00ff">CheckMate 274 (adjuvant nivolumab)</span>''' | ||
** '''Population: 709 patients with high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma of the bladder, ureter, or renal pelvis,''' with or without neoadjuvant cisplatin-based therapy | ** '''Population: 709 patients with high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma of the bladder, ureter, or renal pelvis,''' with or without neoadjuvant cisplatin-based therapy | ||